The development of projective metric method for analyzing star positions

© Published under licence by IOP Publishing Ltd. In this work, the projective geometry method was used for analyzing star clusters. When carrying out the calculation procedures, it was considered that non-linear distortion factors had been removed from the measured stars' coordinates. Determination of stars' proper motions is of great practical importance, as the inertial coordinate system relies on catalogues of star positions, and it is necessary to be aware of the stellar reference marks' time shift. In the practical part of the work, the breadboard simulation of the use of the proposed method for determining stars' proper motions is performed. At the same time, it is supposed that at 90"/mm breadboard image scale the absolute values of proper motions do not exceed 0.050"over a period of 50 years. As result, determined that the standard deviation of the calculated proper motions μα, μβ from their true value is 0.0065 arcseconds for the first model (when the proper motions of the reference "stars"are negligible and equal to 0) and 0.0072 arcseconds or the second model (when the reference stars do have real proper motions). These values indicate the high accuracy of the used method

Stochastic analysis of dynamic processes in the solar activity

Natural processes existing in complex objects of inanimate and living matter are of a stochastic and non-equilibrium nature. The main problem in the study of such systems is to determine the value of entropy as a quantitative measure of the uncertainty and systematicity of states of dynamical systems in different phase spaces. This paper presents a new method for analyzing active processes of solar dynamics using the theory of non-Markov random discrete processes (NMRDP). The NMRDP theory is based on the Zwanzig-Mori kinetic equations in a finite-difference discrete interpretation. This is consistent with the concept of non-equilibrium statistical condensed matter physics. Qualitative information about the set of behavioral patterns, relaxation processes, dynamic characteristics and internal properties of solar activity can be obtained using NMRDP modeling by the author's methodological approach developed in this work. This approach is focused on the analysis of spectral frequency memory functions, dynamic orthogonal parameters, phase transformations, relaxation and kinetic processes and self-organization in complex physical systems. In this work, for modeling NMRDP, the author's software package APSASA (automated program for solar activity stochastic analysis) was used, which also allows predicting the trend of solar activity for a limited period of time. Modeling NMRDP associated with active processes occurring on the Sun made it possible to build a mathematical model with whose help it is possible to study the regularities and randomness of stochastic processes, as well as to reveal the patterns arising from the recurrence and periodicity of solar activity

STUDY OF LONG-TERM CLINICAL AND PATHOGENETIC EFFECTS OF FAVIPIRAVIR-BASED ANTI-VIRAL DRUG IN PATIENTS WITH METABOLIC SYNDROME IN POST-COVID PERIOD [ИЗУЧЕНИЕ ОТДАЛЕННЫХ КЛИНИКО-ПАТОГЕНЕТИЧЕСКИХ ЭФФЕКТОВ ПРОТИВОВИРУСНОГО ЛЕКАРСТВЕННОГО ПРЕПАРАТА НА ОСНОВЕ ФАВИПИРАВИРА В ПОСТКОВИДНОМ ПЕРИОДЕ У ПАЦИЕНТОВ С МЕТАБОЛИЧЕСКИМ СИНДРОМОМ]

The article presents modern scientific data on long-term clinical and pathogenetic effects of the antiviral drug Areplivir (Favipiravir) in patients with metabolic syndrome in the post-COVID period. The aim of the article is to study long-term cytokine-mediated (IL-6/sIL6r and LIF/sLIFr) pathogenetic effects of the favipiravir (Areplivir®) based drug on the incidence of complications in patients with metabolic syndrome in the post-COVID period. Material and methods. With the approval of the local ethics committee at the N.P. Ogarevs Mordovia State University (Protocol No. 5 dated May 17, 2020) “An open prospective comparative study of the Areplivir® (Favipiravir) drug effectiveness in reducing the risk of complications in the post-COVID period in patients with metabolic syndrome” in the Republic of Mordovia was carried out. The study included 190 metabolic syndrome patients who received the outpatient treatment for COVID-19 at Saransk polyclinics from February 2021 to March 2021. The case of COVID-19 was diagnosed in accordance with the current Temporary Guidelines for the prevention, diagnosis and treatment of the new coronavirus infection. Results. The analysis of the metabolic syndrome patients' follow-up within 1 year after undergoing COVID-19, revealed significant differences in the incidence of complications depending on the intake of the favipiravir based drug. The patients who were administrated with favipiravir at the early stage of infection, were characterized by lower serum levels of four members of the interleukin 6 family - IL-6 (IL-6, sIL6r and LIF, sLIFr) 10, 30 and 180 days after a clinical and laboratory recovery (p<0.001). The average statistical changes in the IL-6/sIL6r system of the group administrated with favipiravir, were 90%, and they were higher than in the group not administrated with antiviral drugs. In the group of the patients administrated with favipiravir, there was a significant (p<0.001) positive dynamic of the sLIFr indicator, while in the comparison group, there was an increase in this indicator. A protective effect of the early favipiravir use was characterized by a decrease in the frequency of cardiovascular complications, a 2.66-fold decrease in the risk of a stroke and the ACS in the post-COVID period. Conclusion. The areplivir therapy in the acute period of coronavirus infection made it possible to timely reduce the viral load. It helps to correct the pro-inflammatory vector of the immune response at the post-COVID stage and, accordingly, reduces the risk of progression of atherosclerosis, transient cerebrovascular accidents with a cognitive decline, an endothelial dysfunction, and can be considered a secondary prevention of life-threatening cardiovascular complications. © 2022 Volgograd State Medical University, Pyatigorsk Medical and Pharmaceutical Institute. All rights reserved